Investor relations

RNS announcements

Financial reports

Shareholder circulars

Share price information

Share capital information

Advisors

RNS announcements

Financial reports

Shareholder circulars

Share price information

Share capital information

Advisors

RNS announcements

Financial reports

Shareholder circulars

Share price information

Share capital information

Advisors

RNS announcements

Financial reports

Shareholder circulars

Share price information

Share capital information

Advisors

RNS announcements

Financial reports

Shareholder circulars

Share price information

Share capital information

Advisors

Share capital information

Total shares outstanding:

5,908,770,690

Significant shareholders over 3%:

Name

Shares

%

Pamlico Shoals Targeted Opportunities Fund LP

730,306,344

12.36%

William Potts

610,461,538

10.3%

Nicholas Nelson

205.961,538

3.49%

Governance

Governance report

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Media pack

Media pack

Solvonis Therapeutics

©

2025

Solvonis Therapeutics

Privacy Policy

Site by: Cohesion Labs

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Media pack

Media pack

Solvonis Therapeutics

©

2025

Solvonis Therapeutics

Privacy Policy

Site by: Cohesion Labs

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Media pack

Media pack

Solvonis Therapeutics

©

2025

Solvonis Therapeutics

Privacy Policy

Site by: Cohesion Labs

Solvonis Therapeutics

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Solvonis Therapeutics

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Solvonis Therapeutics

Therapeutic focus

Therapeutic focus

R&D

R&D

Investor relations

Investor relations

About

About

News

News

Contact

Contact

Solvonis Therapeutics

Menu

Solvonis Therapeutics

Menu